He is known for his gritty portrayals of villains. Now, Keith has undergone a massive physical and professional shift.

Structured de-escalation of GLP-1 receptor agonists may lead to sustained health benefits while reducing treatment burden, ...

The online health platform Hers has launched a new weight loss membership for GLP-1 treatments. The membership starts at $39 for the first month and then costs $149 per month. Hers offers various ...

The Food and Drug Administration on April 1 approved Eli Lilly's new weight-loss pill, giving consumers a second option in the growing non-injectable GLP-1 weight-loss drug market. Lilly said it will ...

The US Food and Drug Administration on Wednesday approved the second GLP-1 pill for weight loss, adding another option to a rapidly growing arsenal of obesity therapies. The orforglipron pill, called ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. INDIANAPOLIS, INDIANA - MARCH 17: A flag flies above the headquarters campus of Eli Lilly ...

Lilly pill led to 12%-15% reduction in body weight in clinical trials Will be sold as Foundayo and available beginning April 6 FDA fast-tracked approval under Trump-era voucher program The Lilly drug, ...

The drug, made by Eli Lilly, could offer a more convenient option for patients who want to avoid injections. By Dani Blum and Rebecca Robbins The Food and Drug Administration on Wednesday approved a ...

You’ve heard of the popular glucagon-like peptide-1 (GLP-1) receptor agonist drug semaglutide (Ozempic, Wegovy) and GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound). Now there’s a new kid on the weight ...

Of all the millions of people who have tried weight-loss drugs such as Wegovy and Zepbound, nearly one in four people don’t respond to treatment. They lose little weight, or none at all, and see few ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...